Letrozol Genthon

Letrozole, the active ingredient in Letrozol Genthon, is an aromatase inhibitor presented as an oral tablet for systemic use. It is employed in the endocrine treatment of hormone receptor‑positive breast cancer in postmenopausal women and works by reducing estrogen production, which can help slow the growth of estrogen‑dependent tumors.

GNH USA supplies Letrozol Genthon as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. Our distribution network ensures reliable delivery, regulatory compliance, and quality assurance for healthcare providers across Europe, Asia, Africa and the Americas.

Letrozol Genthon is an aromatase inhibitor indicated for hormone‑dependent breast cancer therapy.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen levels to inhibit tumor growth.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Hot flashes - Arthralgia or joint pain - Fatigue - Nausea - Headache - Insomnia

Serious or Rare Side Effects: - Severe liver injury - Osteoporotic fractures - Deep vein thrombosis or pulmonary embolism - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Myocardial infarction - Severe allergic reactions (anaphylaxis)

Before initiating therapy, consider the following safety measures.

- Pregnancy avoidance: contraindicated in pregnancy (Category X). - Breastfeeding: not recommended; avoid during lactation. - Bone health: monitor bone mineral density and consider calcium/vitamin D supplementation. - Hepatic function: assess liver function; adjust use in severe impairment. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Letrozol Genthon may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Strong CYP2C19 inhibitors: may increase letrozole exposure. - Tamoxifen: antagonistic effect on estrogen suppression. - Estrogen replacement therapy: reduces efficacy of letrozole.

Moderate Interactions (Monitor Closely): - Warfarin: may alter INR and increase bleeding risk. - CYP3A4 inducers (e.g., rifampin): may reduce plasma levels of letrozole. - Selective serotonin reuptake inhibitors (SSRIs): possible additive effect on hot flash reduction.